CARLSBAD, CA, Carlsmed announced today that it closed an oversubscribed $30 million Series B funding round, led by B Capital Group.
Existing investors, U.S. Venture Partners, The Vertical Group, Cove Fund and Wavemaker Three-Sixty Health, also participated in the round. The company plans to use the Series B funds to ramp commercialization of aprevo¬®, Carlsmed's FDA cleared personalized surgical devices.
Carlsmed's mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company's aprevo¬® devices are personalized to improve the standard of care for the surgical treatment of adults with spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create aprevo¬® spine fusion devices to align with the surgeon's goals for each patient.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about